Imugene Ltd

As of June 30, 2025, Imugene Ltd carries a market capitalization of 97.07M, placing it among publicly traded companies globally. Its enterprise value stands at 85.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Imugene Ltd's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, Imugene Ltd has 219.62M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Imugene Ltd maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Imugene Ltd posted a negative return on equity (ROE) of -84.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -58.75, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Imugene Ltd's stock has declined approximately 89.60% over the past 52 weeks. The 50-day moving average sits at 0.05, while the 200-day moving average is 0.14.

These figures cover the twelve months ended June 30, 2025. EBITDA reached -85.06M, while operating income came in at -85.96M.

As of June 30, 2025, Imugene Ltd holds 21.94M in cash and equivalents against 10.65M in total debt, resulting in a net debt position of -12.69M. Total book value stands at 45.03M, with working capital of 19.59M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -17.90, meaning Imugene Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Imugene Ltd's most recent stock split took place on July 11, 2025 with a 34:1 split ratio.